EVOLUS, INC. Net Income (Loss) Available to Common Stockholders, Basic
EVOLUS, INC. (EOLS) reported Net Income (Loss) Available to Common Stockholders, Basic of -$17.40 million for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-05-10
- EVOLUS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2022-03-31 was -$17.40M, a 371.80% decline year-over-year.
- EVOLUS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was $6.40M.
- EVOLUS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2020-03-31 was -$19.73M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month |
|---|---|
| 2022-03-31 | -$17.40M 10-Q · filed 2022-05-10 |
| 2021-03-31 | $6.40M 10-Q · filed 2022-05-10 |
| 2020-03-31 | -$19.73M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |